Rho

Rho

Biotechnology Research

Durham, North Carolina 31,754 followers

Experience, Rho. A global full-service CRO.

About us

Changing what it means to work with a global CRO. At Rho, we believe expertise is everything. With team members spanning continents, we bring together the brightest minds in the industry. With a demonstrated track record of success, we guide our clients through the most appropriate program strategies, navigate the unique challenges of clinical trials, and drive development of the high-quality marketing applications demanded by regulatory authorities. Sparked by a shared mission to improve lives, our experts take clients beyond procedural operations and into truly proactive problem-solving. Through a collaborative approach and individualized attention, our focus is advancing your program so that, together, we can help heal the world. That is what drives us. Experience, Rho.

Website
http://www.rhoworld.com
Industry
Biotechnology Research
Company size
501-1,000 employees
Headquarters
Durham, North Carolina
Type
Privately Held
Founded
1984
Specialties
Clinical Trial Management, IND & NDA Submissions, Protocol Development, Regulatory Strategy, Program Management, Site Selection & Start-up, Adaptive Trial Design, Clinical Monitoring, Biostatistics, Clinical Data Management, CDISC, IVRS, IWR, Randomization, Decentralized & Virtual Clinical Trials, Risk-Based Quality Management, Rare Disease Clinical Trials, Analgesia Clinical Trials, Infectious Disease Clinical Trials, CNS Clinical Trials, Neurology Clinical Trials, and Psychiatry Clinical Trials

Locations

Employees at Rho

Updates

  • View organization page for Rho, graphic

    31,754 followers

    This is what 40 years of a strong culture and company mission looks like! It was a vibrant, active week at Rho's Durham office this week. From our "Techapalooza" where members of our IT team hosted sessions on our tech stack to our big, international 40-year anniversary celebration, our office was buzzing with activity and colleagues (and their families)! Our global colleagues in the Ukraine, Latvia, and Poland joined in from their locations, as well, many bringing their families along for the celebration, too. The entire Rho team is ready to dive into our next decade! Want to join us? Check out job openings: https://lnkd.in/eWtAm8vc

    • No alternative text description for this image
    • No alternative text description for this image
    • No alternative text description for this image
    • No alternative text description for this image
    • No alternative text description for this image
      +5
  • View organization page for Rho, graphic

    31,754 followers

    Navigating the complexities of rare disease drug development requires a strategic approach, especially when it comes to statistical challenges. Early and frequent communication with regulatory authorities can pave the way for novel statistical methods. Learn more about how to effectively engage with the FDA and other agencies to overcome these hurdles. Dive into our latest blog post for detailed insights from our Associate Director, Biostatistics, Patricia Stephenson: https://bit.ly/3xOdBVd

    Overcoming statistical challenges in rare disease drug development | Rho

    Overcoming statistical challenges in rare disease drug development | Rho

    https://www.rhoworld.com

  • View organization page for Rho, graphic

    31,754 followers

    Big congratulations to Swing Therapeutics, Inc. on the outstanding results published today! This is a gamechanger for the fibromyalgia community, offering new hope and relief. We are excited to see the continued positive impacts from this work!

    View profile for Ben Vaughn, graphic

    Chief Strategist Biostatistics and Protocol Design at Rho

    As drug developers, it's easy to overlook non-pharmacological solutions. Swing Therapeutic's Stanza data published today in The Lancet show a promising solution for fibromyalgia patients without drug side effects. This group was amazing to work with and the adaptive protocol design posed some unique challenges applying drug-division lessons learned to a device trial. Hit me up for the full-text author link!

    Swing Therapeutics Announces The Lancet Publication of Data from Phase 3 Trial of Stanza™ - a Digital Behavioral Therapy for Fibromyalgia Symptoms

    https://swingtherapeutics.com

  • Rho reposted this

    View organization page for Parkinson's Foundation, graphic

    20,342 followers

    🚨 Breaking News: President Biden has signed the National Plan to End Parkinson’s Act into law! This is the first-ever federal legislation dedicated to ending Parkinson’s disease. This monumental bill can make an impact by: 💵 Dramatically increasing federal research funding 🔬 Developing more effective pathways for treatments and cures 🩺 Improving early diagnosis 🥼 Sparking new and improved models for patient care ⚖️ Addressing health disparities in diagnosis, treatment, and clinical trial participation We would like to thank all the Parkinson’s advocates, volunteers and people who wrote to their senators and representatives to make this bill become law. “The Parkinson’s Foundation is excited for what comes next,” said John Lehr, Parkinson’s Foundation President and CEO. “We look forward to having input in designing exactly how this bill will mobilize meaningful change for the one million Americans living with this disease.” Learn more: https://lnkd.in/gNU9tYc8

    • No alternative text description for this image
  • View organization page for Rho, graphic

    31,754 followers

    We are excited that, earlier this year, FDA has approved Xolair as the first medicine for reducing allergic reactions to multiple food allergens in patients aged one year and older as a result of the NIH-sponsored Phase III OUtMATCH study. Rho is proud to have been a part of this achievement in food allergy research. For more information about the study, visit bit.ly/NewsFoodAllergies Here’s why this is so important to so many people: Food allergies have increased significantly over the last two decades, putting more people at risk for severe reactions. With food allergies being the most common cause of anaphylaxis, it's encouraging to see groundbreaking advancements in allergy treatment. 

    • No alternative text description for this image
  • View organization page for Rho, graphic

    31,754 followers

    We are firm believers that an active lifestyle and time spent outdoors can have a huge impact on an individual's overall well-being. As we spend more time outside, it is important to recognize the negative effects of prolonged sun exposure. Harmful UV radiation can lead to sunburn, premature aging, and even skin cancer. Sun exposure can also worsen existing skin conditions due to increased inflammation, sensitivity, and hyperpigmentation. Everyone should protect themselves against the sun, but those with pre-existing skin concerns should be extra cautious to prevent exacerbating their condition. #SunSafety #DermatologyCRO #SkinProtection

    • No alternative text description for this image
  • View organization page for Rho, graphic

    31,754 followers

    We are humbled to announce that we have been recognized by Triangle Business Journal as one of the 2024 Best Places to Work! This honor reflects the culture our team has fostered over the last 40 years. We applaud our employees for their collaborative spirit, trust and support of one another, openness to adaptability and innovation, and dedication to our purpose to improve health. Our team’s commitment to live out our values every day is what makes Rho a great place to work. That’s what it means to #ExperienceRho

    • No alternative text description for this image
  • View organization page for Rho, graphic

    31,754 followers

    Congratulations Peter Schmidt, on your groundbreaking paper! We look forward to seeing how this work influences future studies and clinical practices. Well done!

    View profile for Peter Schmidt, graphic

    Chief Scientific Officer at Rho

    I'm very pleased to have a new paper out representing a capstone to my long research focus on exercise and rehabilitation in Parkinson's. Starting with observational cohort studies showing that exercise was a common characteristic of people who lived long with high quality of life in PD, through funding programs and organizing research, we found that exercise programs are feasible, replicable, and provide a lasting benefit. This paper describes an initiative conducted across Italian centers, working with brilliant, patient-focused clinicians, and I contributed a protocol and CRF for outcome measurement. The work was funded by a private foundation led by the veteran industrialist, Paolo Fresco, and made possible by my friends and colleagues Monica Norcini, Angelo Quartarone, Lice Gilhardi, and Sheng Luo. https://lnkd.in/gEKnaCmh

    Supplementing Best Care with Specialized Rehabilitation Treatment in Parkinson’s Disease: A Retrospective Study by Different Expert Centers

    Supplementing Best Care with Specialized Rehabilitation Treatment in Parkinson’s Disease: A Retrospective Study by Different Expert Centers

    mdpi.com

Similar pages

Browse jobs